Ventyx Biosciences IncNASDAQ:VTYX
- LAST PRICE4.9518
- TODAY'S CHANGE (%)0.7618 (18.1814%)
- Bid / Lots4.9500/ 5
- Ask / Lots4.9700/ 3
- Open / Previous Close4.4100 / 4.1900
- Day Range
- 52 Week Range
- Volume968,111
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VTYX |
|---|---|---|
| 09:32 ET | 22216 | 4.46 |
| 09:34 ET | 652 | 4.4316 |
| 09:36 ET | 10547 | 4.5 |
| 09:38 ET | 21991 | 4.57 |
| 09:39 ET | 8321 | 4.56 |
| 09:41 ET | 22754 | 4.56 |
| 09:43 ET | 1815 | 4.57 |
| 09:45 ET | 12254 | 4.4904 |
| 09:48 ET | 1260 | 4.52 |
| 09:50 ET | 5652 | 4.51 |
| 09:52 ET | 13423 | 4.4516 |
| 09:54 ET | 3850 | 4.48 |
| 09:56 ET | 4362 | 4.54 |
| 09:57 ET | 4023 | 4.5384 |
| 09:59 ET | 2014 | 4.53 |
| 10:01 ET | 1820 | 4.55 |
| 10:03 ET | 200 | 4.565 |
| 10:06 ET | 1150 | 4.56 |
| 10:08 ET | 5197 | 4.56 |
| 10:10 ET | 4229 | 4.5684 |
| 10:12 ET | 4469 | 4.6 |
| 10:14 ET | 1941 | 4.6188 |
| 10:15 ET | 950 | 4.61 |
| 10:19 ET | 6338 | 4.68 |
| 10:21 ET | 5635 | 4.69 |
| 10:24 ET | 9958 | 4.69 |
| 10:26 ET | 550 | 4.66 |
| 10:28 ET | 516 | 4.675 |
| 10:30 ET | 44618 | 4.7372 |
| 10:32 ET | 28816 | 4.6917 |
| 10:33 ET | 5606 | 4.74 |
| 10:35 ET | 962 | 4.725 |
| 10:37 ET | 1291 | 4.74 |
| 10:39 ET | 2620 | 4.7678 |
| 10:42 ET | 17627 | 4.8183 |
| 10:44 ET | 18512 | 4.71 |
| 10:46 ET | 600 | 4.74 |
| 10:50 ET | 35738 | 4.819 |
| 10:51 ET | 27546 | 4.825 |
| 10:53 ET | 8870 | 4.81 |
| 10:55 ET | 11258 | 4.7883 |
| 10:57 ET | 6886 | 4.8587 |
| 11:00 ET | 6526 | 4.8425 |
| 11:02 ET | 6759 | 4.9195 |
| 11:04 ET | 52004 | 5.0198 |
| 11:06 ET | 22255 | 4.9718 |
| 11:08 ET | 22283 | 4.98 |
| 11:09 ET | 31752 | 4.9318 |
| 11:11 ET | 4939 | 4.98 |
| 11:13 ET | 5648 | 4.9618 |
| 11:15 ET | 7390 | 4.93 |
| 11:18 ET | 12557 | 4.87 |
| 11:20 ET | 37619 | 4.8666 |
| 11:22 ET | 672 | 4.865 |
| 11:24 ET | 4887 | 4.85 |
| 11:26 ET | 5776 | 4.886 |
| 11:27 ET | 3646 | 4.899 |
| 11:29 ET | 1570 | 4.919 |
| 11:31 ET | 2570 | 4.88 |
| 11:33 ET | 2566 | 4.91 |
| 11:36 ET | 2783 | 4.93 |
| 11:38 ET | 9173 | 4.9103 |
| 11:40 ET | 5313 | 4.9123 |
| 11:42 ET | 7100 | 4.9101 |
| 11:44 ET | 300 | 4.92 |
| 11:45 ET | 1500 | 4.94 |
| 11:47 ET | 2141 | 4.91 |
| 11:49 ET | 200 | 4.89 |
| 11:51 ET | 4551 | 4.8712 |
| 11:54 ET | 8691 | 4.9 |
| 11:56 ET | 826 | 4.9088 |
| 11:58 ET | 7551 | 4.9112 |
| 12:00 ET | 421 | 4.9112 |
| 12:02 ET | 7353 | 4.8812 |
| 12:03 ET | 3801 | 4.93 |
| 12:05 ET | 6274 | 4.94 |
| 12:07 ET | 4737 | 4.88 |
| 12:09 ET | 827 | 4.8812 |
| 12:12 ET | 820 | 4.8998 |
| 12:14 ET | 1271 | 4.9012 |
| 12:16 ET | 5739 | 4.9389 |
| 12:18 ET | 1160 | 4.94 |
| 12:20 ET | 24717 | 4.93 |
| 12:21 ET | 899 | 4.9306 |
| 12:23 ET | 400 | 4.94 |
| 12:25 ET | 300 | 4.95 |
| 12:27 ET | 7338 | 4.98 |
| 12:30 ET | 13662 | 4.96 |
| 12:32 ET | 1618 | 4.98 |
| 12:34 ET | 4418 | 4.925 |
| 12:36 ET | 1958 | 4.93 |
| 12:38 ET | 4620 | 4.94 |
| 12:39 ET | 3970 | 4.96 |
| 12:41 ET | 1119 | 4.97 |
| 12:43 ET | 1363 | 4.98 |
| 12:45 ET | 1831 | 4.97 |
| 12:48 ET | 100 | 4.9651 |
| 12:50 ET | 6921 | 4.965 |
| 12:54 ET | 1780 | 4.9695 |
| 12:56 ET | 10074 | 4.9611 |
| 12:57 ET | 1714 | 4.97 |
| 12:59 ET | 261 | 4.975 |
| 01:01 ET | 351 | 4.975 |
| 01:03 ET | 100 | 4.9788 |
| 01:06 ET | 1426 | 4.975 |
| 01:08 ET | 521 | 4.9715 |
| 01:10 ET | 1014 | 4.98 |
| 01:12 ET | 864 | 4.9721 |
| 01:14 ET | 200 | 4.98 |
| 01:15 ET | 200 | 4.975 |
| 01:17 ET | 2370 | 4.9605 |
| 01:19 ET | 605 | 4.95 |
| 01:21 ET | 1888 | 4.945 |
| 01:24 ET | 1125 | 4.9397 |
| 01:26 ET | 5455 | 4.92 |
| 01:28 ET | 2198 | 4.9402 |
| 01:30 ET | 6436 | 4.9751 |
| 01:32 ET | 835 | 4.9785 |
| 01:33 ET | 1640 | 4.9711 |
| 01:35 ET | 950 | 4.995 |
| 01:37 ET | 11072 | 4.935 |
| 01:39 ET | 8596 | 4.9395 |
| 01:42 ET | 706 | 4.95 |
| 01:46 ET | 566 | 4.9501 |
| 01:48 ET | 450 | 4.96 |
| 01:50 ET | 1200 | 4.96 |
| 01:51 ET | 1200 | 4.955 |
| 01:53 ET | 964 | 4.9612 |
| 01:55 ET | 1306 | 4.98 |
| 01:57 ET | 2687 | 4.98 |
| 02:00 ET | 1001 | 4.9712 |
| 02:04 ET | 2400 | 4.96 |
| 02:06 ET | 315 | 4.9518 |
Today
May 14, 2024
NASDAQ INVESTIGATION NOTIFICATION Leading Law Firm BFA LLP Alerts VTYX Investors that Directors of Ventyx Biosciences Are Being Investigated for Potential Breaches of Fiduciary Duty, from 4:12PM ET on Tuesday May 14, 2024 by Dow Jones
4:12PM ET on Tuesday May 14, 2024 by Dow JonesVENTYX BIOSCIENCES, INC. (NASDAQ: VTYX) SHAREHOLDER ALERT: The Directors of Ventyx Biosciences, Inc. Are Being Investigated for Potential Breaches of Fiduciary Duty by Leading Law Firm Bleichmar Fonti & Auld LLP; Contact the Firm for More Details, from 8:37AM ET on Tuesday May 14, 2024 by Dow Jones
8:37AM ET on Tuesday May 14, 2024 by Dow Jones
May 13, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ventyx Biosciences Inc | 295.4M | -1.5x | --- |
Opthea Ltd | 294.1M | -1.4x | --- |
Invivyd Inc | 293.3M | -1.3x | --- |
Actinium Pharmaceuticals Inc | 289.8M | -5.7x | --- |
Inozyme Pharma Inc | 288.9M | -3.4x | --- |
Black Diamond Therapeutics Inc | 306.0M | -3.1x | --- |
Company Information
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Company’s pipeline includes VTX002 (S1P1R Modulator), VTX958 (TYK2 Inhibitor), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is an oral, selective clinical-stage inhibitor of tyrosine kinase type 2 (TYK2), an intracellular signaling kinase in the Janus kinase (JAK) family that regulates chronic inflammation in immune-mediated diseases. Its third product candidate, VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. In addition to VTX2735, it is also developing VTX3232, its lead CNS-penetrant NLRP3 inhibitor in Phase 1 development.
Contact Information
- Headquarters
- 12790 El Camino Real, Suite 200SAN DIEGO, CA, United States 92130
- Phone
- 858-945-2393
- Fax
- 302-655-5049
Executives
- Executive Chairperson of the Board
- Sheila Gujrathi
- President, Chief Executive Officer, Founder, Director
- Raju Mohan
- Chief Financial Officer
- Martin Auster
- Chief Scientific Officer
- John Nuss
- Independent Director
- Onaiza Cadoret-manier
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $295.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 70.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.24 |
Book Value | $4.12 |
P/E Ratio | -1.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
